ACTRN12624000785505尚未招募1 期
A Phase 1 Dose Escalation Safety Study of PBI-671 in Subjects with Glaucoma with Advanced Vision Loss
Perceive Pharma, Inc.0 个研究点目标入组 13 人开始时间: 2024年6月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 13
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Eligible subjects will have been diagnosed with glaucoma with advanced vision loss with the following characteristics:
- •1) Has substantial vision loss, but retains the ability to fixate for SD-OCT acquisition in at least the study eye.
- •2) Is unlikely to substantially benefit from an additional, commercially approved topical medication for glaucoma.
- •3) Is anticipated to remain on stable ocular drug therapy (other than the study drug), including IOP-lowering therapy (as needed), without surgery during the course of the study.
排除标准
- •Confounding ophthalmic and systemic diseases, medications, or therapies.
- •Allergy to study drug or excipient.
研究者
相似试验
尚未招募
1 期
A Phase 1 Study for patients with advanced solid tumors.CTRI/2011/12/002225Orchid Research Laboratories Ltd36
已完成
不适用
A Phase I, Dose Escalation Study on the Safety, Pharmacokinetics and Pharmacodynamics of Coagulation Factor VIIa (Recombinant) and its Comparability to NovoSeven® in Healthy Male Volunteers Pre-Treated with Fondaparinuxhaemophilia10064477NL-OMON34613Centre for Human Drug Research36
招募中
1 期
Effect of briquilimab in patients with patches of itching skin because of chronic spontaneous urticaria (CSU) despite treatment with antihistaminesChronic Spontaneous UrticariaMedDRA version: 20.0Level: PTClassification code: 10072757Term: Chronic spontaneous urticaria Class: 100000004858CTIS2023-505446-25-00Jasper Therapeutics Inc.47
终止
1 期
A phase Ib study of oglufanide disodium (IM862) in patients with chronic HCV infectioChronic Hepatitis CInflammatory and Immune System - Other inflammatory or immune system disordersACTRN12606000505505Implicit Bioscience Pty Ltd32
撤回
不适用
A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients with Stargardt's Macular Degeneration.Fundus flavimaculatusNL-OMON43680Sanofi-aventis6